🚀 Catch an inspiring 3-minute chat with Brian McKernan, CEO of Fluent BioSciences Inc., as he dives into the exciting impact of Fluent’s acquisition by Illumina! Discover how this partnership is set to transform the #healthcare landscape. Download the full conversation from our Spotlight series now 👉 https://lnkd.in/gRnjX9gM #PartnerNews #Biotech #SingleCell #Innovation
Illumina Ventures
Venture Capital and Private Equity Principals
San Francisco, CA 16,890 followers
About us
Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. Our strategic relationship with Illumina provides us access to the expertise and vision of the world's leading genomics solutions provider. Our team members have decades of entrepreneurial experience in genomics and a passion for improving human health.
- Website
-
http://www.illuminaventures.com
External link for Illumina Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- San Francisco, CA
- Type
- Partnership
- Founded
- 2016
- Specialties
- Venture Capital, Genomics, Life Sciences, Private Equity, Precision Medicine, and Start Ups
Locations
-
499 Illinois Street, Suite 210
San Francisco, CA 94158-2509, US
Employees at Illumina Ventures
Updates
-
Illumina Ventures reposted this
𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗡𝗶𝗼™ 𝗙𝗮𝗺𝗶𝗹𝘆: 𝗘𝗹𝗲𝘃𝗮𝘁𝗲 𝗬𝗼𝘂𝗿 𝗟𝗮𝗯'𝘀 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹! Say hello 👋 to the next generation of Digital PCR technology with the Nio™ Line up—our groundbreaking suite designed to transform your lab’s performance. We’re excited to unveil our expanded range of digital PCR instruments, tailored to meet every throughput requirement and engineered to boost your lab's efficiency: ⚫ Nio™ E: The essential digital PCR instrument for streamlined precision. ⚫ Nio™: The flexible solution that adapts to your lab’s evolving needs. ⚫ Nio™+: The ultimate champion for high-demand environments. Schedule your demo with our experts to discover the perfect fit for your lab : https://hubs.la/Q02PhwcG0
-
Kallyope, a clinical stage #biotech company developing novel therapies for unmet medical needs, has entered into a licensing agreement with Novo Nordisk. Novo Nordisk will take over the preclinical and clinical development, manufacturing, and commercialization of a promising ligand discovered by Kallyope, exploring its potential as a new treatment for obesity. “Novo Nordisk is one of the leaders in the discovery and development of therapeutics for obesity and diabetes, and we are excited that our strategic early discovery collaboration resulted in the identification of a promising novel ligand which Novo Nordisk has now licensed,” said Jay Galeota, President and CEO, Kallyope. Read more: https://lnkd.in/edkjZ5st #PartnerNews #DrugDiscovery #DrugDevelopment
-
Next week, our Partner Mara Aspinall will co-chair the White Hat and Arizona BioIndustry Association (AZBio) Awards in Phoenix, honoring leaders from across Arizona who represent the depth and breadth of the region’s #LifeScience industry. Mara is looking forward to an inspiring celebration of #innovation in life sciences September 18-19! Event info: https://lnkd.in/gZZA7npQ
-
LetsGetChecked, a virtual care company offering at-home testing, telehealth services, and pharmacy capabilities, has appointed Melissa Fors Shackelford, MBA, as Senior Vice President of Marketing. Melissa will lead the development and execution of comprehensive marketing strategies across the U.S. #healthcare sector and international markets. “We are thrilled to welcome Melissa to LetsGetChecked,” said Peter Foley, the company’s founder and CEO. “Her exceptional track record driving growth paired with her innovative approach to healthcare marketing will be critical as we continue to expand our services and engage more clients globally.” Read more: https://lnkd.in/ghyC8Cqm #PartnerNews #Diagnostics
-
NanoCellect Biomedical, Inc. has announced a new strategic partnership with DKSH to expand its presence in Southeast Asia. This collaboration aims to enhance business opportunities and introduce NanoCellect’s innovative cell analysis and sorting solutions to more researchers in the life science industry throughout the region. “NanoCellect is excited to collaborate with DKSH. With their established track record, extensive experience, and leading position as the top distributor in the region, they are the ideal partner to facilitate our expansion in the APAC region,” said Paul DiGregorio, Vice President Commercial. “Their proficiency in sales, marketing, application, and after-sales support of flow cytometry products ensure the successful adoption of our innovative solutions in the life science industry. Together with DKSH, we are introducing technologies benefiting researchers in academic and biopharma settings.” Read more: https://lnkd.in/dJf9X5d9 #PartnerNews #CellSorting #FlowCytometry
-
DELFI Diagnostics has appointed Tom Russo as its Chief Financial Officer (CFO). "DELFI is poised to revolutionize cancer screening to better support providers and patients. Tom's appointment expands our capabilities to ensure fiscal excellence, drive adoption at scale, and fulfill the company's potential," said Susan Tousi CEO of DELFI Diagnostics. Read more here: https://lnkd.in/ekauwCr5 #PartnerNews #biotech #DrugDevelopment
-
Research from DELFI Diagnostics published in the Journal of Clinical Medicine (JCM) MDPI explores the #LungCancer screening landscape, obstacles to broader adoption, and how their plasma whole genome fragmentome test (pWGFrag-Lung) can improve screening participation and adherence. This innovative approach has the potential to supplement traditional low-dose computed tomography, making a significant impact on early lung #cancer detection. Read more here: https://lnkd.in/drdxysxp #PartnerNews #biotech #DrugDevelopment
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening
mdpi.com
-
Our portfolio company, Lightcast has published its first peer-reviewed scientific paper in “Lab on a Chip,” a journal from the Royal Society of Chemistry. This publication, developed in collaboration with the University of Cambridge, showcases the potential of Lightcast's novel single-cell functional analysis platform. The platform allows for the simultaneous loading, selection, processing, and analysis of thousands of individual cells, enabling unprecedented control, flexibility, and scalability in single-cell studies. By overcoming the limitations of traditional microfluidics, Lightcast is poised to revolutionize #DrugDiscovery and #LifeScience research. Congratulations to the entire Lightcast team on this significant milestone. Read more: https://lnkd.in/geU9URV9 #PartnerNews #biotech #DrugDevelopment
Lightcast Publishes Seminal Scientific Paper in “Lab on a Chip”
lightcast.bio
-
Susan Tousi, CEO of Ilumina Ventures portfolio company DELFI Diagnostics, recently spoke with Nasdaq about #fragmentomics and its application in DELFI's blood-based FirstLook Test for enhancing #LungCancer screening. The interview also explored the potential of this #technology for screening other #cancer types and monitoring cancer treatment. See the full interview here: https://lnkd.in/e3KfEPEk #partnernews